Active Recombinant Human GCK, His-tagged

• Cat.No.: GCK-199H
• Product Overview: The recombinant Human GCK, His-tagged protein(isoform 2) was expressed in E. coli and purified by affinity chromatography in combination with FPLC columns.

Specification

• Description: Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. Alternative splicing of this gene results in three tissue-specific forms of glucokinase, one found in pancreatic islet beta cells and two found in liver. The protein localizes to the outer membrane of mitochondria. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. Mutations in this gene have been associated with non-insulin dependent diabetes mellitus (NIDDM), maturity onset diabetes of the young, type 2 (MODY2) and persistent hyperinsulinemic hypoglycemia of infancy (PHHI).
• Source: E. coli
• Species: Human
• Tag: His
• Form: The protein is in 20mM Tris-HCl pH7.9,100mM NaCl, 0.2mM EDTA, 1mM DTT and 20% glycerol.
• Bio-activity: 1 unit equals 1 nanogram of purified protein.
• Molecular Mass: 53.1 kDa.
• AA Sequence: MAMDVTRSQA QTALTLVEQI LAEFQLQEED LKKVMRRMQK EMDRGLRLET HEEASVKMLP TYVRSTPEGS EVGDFLSLDL GGTNFRVMLV KVGEGEEGQW SVKTKHQMYS IPEDAMTGTA EMLFDYISEC ISDFLDKHQM KHKKLPLGFT FSFPVRHEDI DKGILLNWTK GFKASGAEGN NVVGLLRDAI KRRGDFEMDV VAMVNDTVAT MISCYYEDHQ CEVGMIVGTG CNACYMEEMQ NVELVEGDEG RMCVNTEWGA FGDSGELDEF LLEYDRLVDE SSANPGQQLY EKLIGGKYMG ELVRLVLLRL VDENLLFHGE ASEQLRTRGA FETRFVSQVE SDTGDRKQIY NILSTLGLRP STTDCDIVRR ACESVSTRAA HMCSAGLAGV INRMRESRSE DVMRITVGVD GSVYKLHPSF KERFHASVRR LTPSCEITFI ESEEGSGRGA ALVSAVACKK ACMLGQ
• Purity: Greater than 95% as determined by SDS-PAGE.
• Applications: It can be used for the phosphorylation of glucose.
• Storage: Stored at -70°C before use. Avoid repeated freeze thaw cycles.

Gene Information

• Gene Name: GCK glucokinase (hexokinase 4) [ Homo sapiens ]
• Official Symbol: GCK
• Synonyms: GCK; glucokinase (hexokinase 4); maturity onset diabetes of the young 2 , MODY2; glucokinase; HK4; HK IV; hexokinase-4; hexokinase-D; hexokinase type IV; hexokinase D, pancreatic isozyme; ATP:D-hexose 6-phosphotransferase; GK; GLK; HHF3; HKIV; HXKP; LGLK; MODY2; FGQTL3
• Gene ID: 2645
• mRNA Refseq: NM_033507
• Protein Refseq: NP_277042
• MIM: 603261
• UniProt ID: P78356
• Chromosome Location: 17q21.2
• Pathway: 3-phosphoinositide biosynthesis, organism-specific biosystem; B Cell Receptor Signaling Pathway, organism-specific biosystem; D-myo-inositol (1,4,5)-trisphosphate biosynthesis, organism-specific biosystem; Inositol phosphate metabolism, organism-specific biosystem; Inositol phosphate metabolism, conserved biosystem; Phosphatidylinositol signaling system, organism-specific biosystem; Phosphatidylinositol signaling system, conserved biosystem
• Function: 1-phosphatidylinositol-4-phosphate 5-kinase activity; 1-phosphatidylinositol-5-phosphate 4-kinase activity; ATP binding; nucleotide binding; receptor signaling protein activity; transferase activity

Reviews

03/22/2021

I confidently recommend the GCK protein to any researcher seeking a superior protein that not only fulfills their experimental needs but is also backed by unparalleled support from the manufacturer.

08/06/2019

This has greatly facilitated my experimental workflow, ensuring a readily available and dependable protein source whenever I need it.

09/23/2018

Its high quality, coupled with the manufacturer's exceptional technical support, make it a reliable and effective choice for addressing my scientific inquiries.

Q&As

Are there ongoing clinical trials focusing on ERBB3 inhibitors?

Clinical trials exploring ERBB3 inhibitors or drugs targeting the ERBB3 pathway are ongoing to evaluate their effectiveness and safety.

Can ERBB3 inhibitors be used in combination with other cancer therapies?

Yes, combining ERBB3 inhibitors with other targeted therapies or chemotherapy is being explored to enhance treatment efficacy.

How does ERBB3 contribute to resistance to certain cancer therapies?

ERBB3 activation has been associated with resistance to some targeted therapies, such as EGFR inhibitors, making it a challenging target in cancer treatment.

Can ERBB3 be used as a biomarker for prognosis in cancer patients?

Yes, elevated ERBB3 expression has been linked to poor prognosis in certain cancers, serving as a potential biomarker for patient outcomes.

How does ERBB3 interact with other receptors in the EGFR family?

ERBB3 can form heterodimers with other EGFR family members, such as EGFR and HER2, leading to the activation of downstream signaling pathways.